Been in this for a little while now since the change in market structure and added a few times to this position so not the best avg weighted entry but still well in profit.
Classic sweep of lows and change in market structure has me excited on this position and more recently over the last month with the gap up above the previous short term high and now the...
After a nice pullback im thinking we may have the higher low set, certainly possible we make a larger correction but I added on that higher low expecting the follow through at some point.
Watching the rising wedge for potential exit signs and a larger potential top 3rd wave top.
Editas Medicine is a clinical stage genome editing company,
With the help of CRISPR technology, it focuses on treating a range of serious diseases like:
-Leber Congenital Amaurosis type 10 (Genetic form of vision loss that leads to blindness in childhood) - EDIT-101 has recently entered phase 1/2 trial for the treatment, the very first time an in vivo CRISPR...
Clearly a lot of value has been lost in the past month. The CSO stepped down and analysts downgraded projected revenue. EDIT has very lucrative candidates in the pipeline treating sickle cell anemia. Long-term, this company will most certainly be profitable, with significant patent protection. This is a short term down draft that is consolidating, for the near...
